HCAT / Health Catalyst, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 HEALTH CATALYST, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Health Catalyst Reports Second Quarter 2025 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2025 Results SALT LAKE CITY, UT, August 7, 2025 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. “For the second quarter of 2025, I am pleased by our strong financial results

© Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, a

q22025earningscallonepag © Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements rega

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 HEALTH CATALYST, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

© Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, a

© Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth a

Health Catalyst Reports First Quarter 2025 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2025 Results SALT LAKE CITY, UT, May 7, 2025 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2025. “For the first quarter of 2025, I am pleased by our strong financial results, in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

Non-Employee Director Compensation Policy

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Health Catalyst, Inc.

© Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, a

© Health Catalyst. Confidential and Proprietary. Note: This summary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth a

Non-Employee Director Compensation Policy.

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Insider Trading Policy

Exhibit 19.1 HEALTH CATALYST, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Health Catalyst, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the

As filed with the U.S. Securities and Exchange Commission on February 26, 2025

As filed with the U.S. Securities and Exchange Commission on February 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Iden

, between the Registrant and

Exhibit 10.11 To: Dan LeSueur February 5, 2024 Dear Dan, We are pleased to extend to you an offer for a new position with Health Catalyst. This offer is subject to Board approval as well as the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for employment; and employment with Health Catalyst (“HC”) is at will. Position: Chief Operating Officer

Agreement and Plan of Merger, dated January 10, 2025, by and among Health Catalyst, Inc., Upfront Healthcare Services, Inc., and the other parties named therein.

Exhibit 2.1 EXECUTION VERSION Agreement and Plan of Merger by and among Health Catalyst, Inc., Traverse Merger Sub I, Inc., Traverse Merger Sub II, LLC, Upfront Healthcare Services, Inc. and WT Representative LLC as the Representative January 10, 2025 SPECIFIC TERMS IN THIS AGREEMENT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE OF A TYPE THAT HEALTH CATALYST, INC. TREATS AS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Health Catalyst Australia PTY LTD (Australia) Health Catalyst UK Ltd (England and Wales) Health Catalyst India Private Limited (India) Health Catalyst Singapore Pte. Ltd. (Singapore) Health Catalyst Middle East FZ-LLC (incorporated within a Free Zone in the UAE) Lumeon Ltd (England and Wales) PatientBond India Private Limited (India) Able

Health Catalyst Reports Fourth Quarter and Year End 2024 Results

Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2024 Results SALT LAKE CITY, UT, February 26, 2025 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024. “For the full year 2024, I am pleased to share t

JOINT FILING AGREEMENT

Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Health Catalyst, Inc.

Health Catalyst Signs Definitive Agreement to Acquire Upfront Healthcare Services

Exhibit 99.1 Health Catalyst Signs Definitive Agreement to Acquire Upfront Healthcare Services SALT LAKE CITY, UT, January 13, 2025 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. (“Upfront”), a ne

© Health Catalyst. Overview Presentation January 2025 © Health Catalyst. This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this p

© Health Catalyst. Overview Presentation January 2025 © Health Catalyst. This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plan

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

© Health Catalyst. Preliminary Results(1) & Forward-Looking Targets(2) Q4 Financials • Revenue of $78.75M to $79.75M (+6%), in prior range, but with a few minor project delays; Tech Revenue of $50.6M to $51.6M (+9%) • Adj. EBITDA(3) of $7.9M (+480%,

© Health Catalyst. Preliminary Results(1) & Forward-Looking Targets(2) Q4 Financials • Revenue of $78.75M to $79.75M (+6%), in prior range, but with a few minor project delays; Tech Revenue of $50.6M to $51.6M (+9%) • Adj. EBITDA(3) of $7.9M (+480%, 10% Margin), above midpoint of range Full Year Financials • Revenue of $305.7M to $306.7M (+3%), in prior range; Tech Revenue of $194.0M to $195.0M (+

HCAT / Health Catalyst, Inc. / Point72 Asset Management, L.P. - HEALTH CATALYST, INC. Passive Investment

SC 13G/A 1 p24-3231sc13ga.htm HEALTH CATALYST, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Health Catalyst, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 42225T107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che

HCAT / Health Catalyst, Inc. / First Light Asset Management, LLC - SCHEDULE 13G Passive Investment

SC 13G 1 hcat-sc13g093024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Health Catalyst, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 42225T107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of HEALTH CATALYST, INC.

HCAT / Health Catalyst, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

Nationally Recognized Healthcare Executive Dr. Jill Hoggard Green Joins Health Catalyst Board of Directors

Exhibit 99.4 Nationally Recognized Healthcare Executive Dr. Jill Hoggard Green Joins Health Catalyst Board of Directors Salt Lake City, Utah – November 6, 2024 – Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jill Hoggard Green, RN, BSN, MS, PhD, FAAN, former Chief Executive

Health Catalyst Reports Third Quarter 2024 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2024 Results SALT LAKE CITY, UT, November 6, 2024 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2024. “For the third quarter of 2024, I am pleased with our strong financial

© Health Catalyst. • Health system operating margin improvement and stabilization compared to 2022 and most of 2023 continues to be a medium-term bookings tailwind • Client wins: CyncHealth, a new Ninja Universe Ignite client; OrthoNebraska, a new Ig

© Health Catalyst. • Health system operating margin improvement and stabilization compared to 2022 and most of 2023 continues to be a medium-term bookings tailwind • Client wins: CyncHealth, a new Ninja Universe Ignite client; OrthoNebraska, a new Ignite client; WISHIN, a Ninja Universe Ignite client expansion • Continued expectation of return to double-digit topline growth in 2025; as is always t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Signs Definitive Agreement to Acquire Top-Rated Cybersecurity Provider, Intraprise Health

Exhibit 99.3 Health Catalyst Signs Definitive Agreement to Acquire Top-Rated Cybersecurity Provider, Intraprise Health Salt Lake City, Utah – November 6, 2024 – Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Intraprise Health, LLC (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Credit Agreement, dated July 16, 2024, between the Registrant and Silver Point Finance, LLC

Exhibit 10.1 Execution Version SENIOR SECURED CREDIT FACILITIES CREDIT AGREEMENT dated as of July 16, 2024, among HEALTH CATALYST, INC., as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO, and SILVER POINT FINANCE, LLC as Administrative Agent, as Sole Lead Arranger and Bookrunner SPECIFIC TERMS IN THIS AGREEMENT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE OF A TYPE

© Health Catalyst. • In 1H 2024 we signed more net new Platform Subscription Clients than in all of 2023, and our updated expectations of low-20s net new Platform Subscription Clients would represent the strongest year in the company’s history for th

© Health Catalyst. • In 1H 2024 we signed more net new Platform Subscription Clients than in all of 2023, and our updated expectations of low-20s net new Platform Subscription Clients would represent the strongest year in the company’s history for this metric. • We announced multiple client wins including: SingHealth, the largest group of healthcare organizations in Singapore, and Adena, a 4-hospi

Health Catalyst Reports Second Quarter 2024 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2024 Results SALT LAKE CITY, UT, August 7, 2024 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2024. “For the second quarter of 2024, I am pleased by our strong financial results

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Health Catalyst Announces New Credit Facility for up to $225,000,000

Exhibit 99.1 Health Catalyst Announces New Credit Facility for up to $225,000,000 Salt Lake City, Utah – July 18, 2024 – Health Catalyst, Inc. (“Health Catalyst” or the “Company”) (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has entered into a five-year term loan facility for up to $225,000,000 (the “Credit Facilit

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Separation and Release Agreement, dated April 1, 2024, between the Registrant and Bryan Hunt.

Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) is made and entered into as of the last date on the signature page (the “Effective Date”) and confirms the following understandings and agreements among Health Catalyst, Inc. (“Health Catalyst” or the “Company”) and Bryan Hunt (hereinafter referred to as “you” or “your”). WHEREAS, you were employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

Non-Employee Director Compensation Policy

Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiari

© Health Catalyst Proprietary. • Health system operating margins continue to improve vs. 2022 and most of 2023; we anticipate this will be a bookings tailwind in 2024 and beyond. • Our next-generation data and analytics platform will be branded Healt

© Health Catalyst Proprietary. • Health system operating margins continue to improve vs. 2022 and most of 2023; we anticipate this will be a bookings tailwind in 2024 and beyond. • Our next-generation data and analytics platform will be branded Health Catalyst Ignite. • We’re encouraged to see pipeline development and growth across new and existing clients, including technology, services and TEMS.

Health Catalyst Reports First Quarter 2024 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2024 Results SALT LAKE CITY, UT, May 9, 2024 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2024. “For the first quarter of 2024, I am pleased by our strong financial results, in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

* * * *

Via EDGAR Transmission April 23, 2024 Division of Corporation Finance Office of Technology U.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Health Catalyst, Inc.

As filed with the U.S. Securities and Exchange Commission on February 16, 2024

As filed with the U.S. Securities and Exchange Commission on February 16, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Iden

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

© Health Catalyst Proprietary. • While health system operating margins continue to be challenged relative to longer-term historical levels, we are encouraged to see operating margins steadily improving in recent months; we anticipate this will be a t

© Health Catalyst Proprietary. • While health system operating margins continue to be challenged relative to longer-term historical levels, we are encouraged to see operating margins steadily improving in recent months; we anticipate this will be a tailwind related to our bookings metrics in 2024 and beyond. • Our meaningful investment and early rollout of the next-generation of our data platform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Non-Employee Director Compensation Policy.

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

, between the Registrant and Anne Marie Bickmore.

Exhibit 10.13 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) is made and entered into as of the last date on the signature page (the “Effective Date”) and confirms the following understandings and agreements among Health Catalyst, Inc. (“Health Catalyst” or the “Company”) and Anne Marie Bickmore (hereinafter referred to as “you” or “your”). WHEREAS, you we

© Health Catalyst Proprietary. Health Catalyst Updated Growth & Financial Targets (1) High-level estimated business unit adjusted EBITDA margin analysis. Estimated business unit contribution profit for Technology and Professional Services based on al

© Health Catalyst Proprietary. Health Catalyst Updated Growth & Financial Targets (1) High-level estimated business unit adjusted EBITDA margin analysis. Estimated business unit contribution profit for Technology and Professional Services based on allocating adjusted gross margin and operating expenses by business unit. Adjusted gross margin segmented by Technology and Professional Services. Opera

Health Catalyst Reports Fourth Quarter and Year End 2023 Results

Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2023 Results SOUTH JORDAN, UT, February 22, 2024 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2023. “For the full year 2023, I am pleased to share tha

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Health Catalyst Australia PTY LTD (Australia) Health Catalyst UK Ltd (England and Wales) Health Catalyst India Private Limited (India) Health Catalyst Singapore Pte. Ltd. (Singapore) Health Catalyst Middle East FZ-LLC (incorporated within a Free Zone in the UAE) Able Health, LLC (Delaware, United States) ARMUS I LLC (Delaware, United State

Policy for Recovery of Erroneously Awarded Compensation

Exhibit 97 HEALTH CATALYST, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Health Catalyst, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Policy Th

HCAT / Health Catalyst, Inc. / Point72 Asset Management, L.P. - HEALTH CATALYST, INC. Passive Investment

SC 13G/A 1 p24-0507sc13ga.htm HEALTH CATALYST, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Health Catalyst, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec

HCAT / Health Catalyst, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01090-healthcatalystinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Health Catalyst Inc Title of Class of Securities: Common Stock CUSIP Number: 42225T107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to design

HCAT / Health Catalyst, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

© Health Catalyst. Confidential and Proprietary. Preliminary 2023 Financial Updates & Forward-Looking Commentary 1 • Preliminary Q4 2023 Total Revenue results above guidance midpoint (range of $70.1M to $75.1M) • Preliminary Q4 2023 Adjusted EBITDA r

jpm2024excerpt © Health Catalyst. Confidential and Proprietary. Preliminary 2023 Financial Updates & Forward-Looking Commentary 1 • Preliminary Q4 2023 Total Revenue results above guidance midpoint (range of $70.1M to $75.1M) • Preliminary Q4 2023 Adjusted EBITDA results at or above guidance midpoint (range of $0.3M to $2.3M) • Preliminary FY 2023 Total Revenue results above guidance midpoint (ran

© Health Catalyst. Confidential and Proprietary. Overview Presentation January 2024 © Health Catalyst. Confidential and Proprietary. This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements

jpm2024presentation © Health Catalyst. Confidential and Proprietary. Overview Presentation January 2024 © Health Catalyst. Confidential and Proprietary. This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 HEALTH CATALYST,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

© Health Catalyst. Confidential and Proprietary. Health Catalyst Q3 2023 Financial Highlights & Key Themes 1 • Announced meaningful new DOS client partnership with Accountable Health Partners, a Clinically Integrated Network in greater Rochester with

© Health Catalyst. Confidential and Proprietary. Health Catalyst Q3 2023 Financial Highlights & Key Themes 1 • Announced meaningful new DOS client partnership with Accountable Health Partners, a Clinically Integrated Network in greater Rochester with roughly 400,000 patients • Accountable Health Partners will leverage the DOS data platform, including Healthcare.AI, and a subset of applications, su

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Reports Third Quarter 2023 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2023 Results SALT LAKE CITY, UT, November 2, 2023 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2023. “For the third quarter of 2023, I am pleased by our strong financial re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 HEALTH CATALYST,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Reports Third Quarter 2023 Preliminary Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2023 Preliminary Results SALT LAKE CITY, UT, October 27, 2023 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported preliminary financial results for the quarter ended September 30, 2023. Given recent market and sector dynamics, we are

Non-Employee Director Compensation Policy.

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

© Health Catalyst. Confidential and Proprietary. 5-year, ~$50M contract with long-standing regional health system client: • Includes All-Access Technology and TEMS in new offering area (ambulatory operations) • Contract roughly quintuples the size of

hcatearningscallsummary © Health Catalyst. Confidential and Proprietary. 5-year, ~$50M contract with long-standing regional health system client: • Includes All-Access Technology and TEMS in new offering area (ambulatory operations) • Contract roughly quintuples the size of the client relationship • Annual spend represents ~5% of the client’s net patient revenue • Includes opportunity to earn annu

Health Catalyst Reports Second Quarter 2023 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2023 Results SALT LAKE CITY, UT, August 8, 2023 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2023. “For the second quarter of 2023, we are encouraged by our financial results,

HCAT / Health Catalyst Inc / Point72 Asset Management, L.P. - HEALTH CATALYST, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Health Catalyst, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 42225T107 (CUSIP Number) July 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p23-2083exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 HEALTH CATALYST, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Offer Letter, dated March 27, 2023, between the Registrant and Ben Landry

Exhibit 10.2 March 27, 2023 Dear Ben, We are pleased to extend to you an offer for a new position with Health Catalyst. This offer is subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for employment; and employment with Health Catalyst (“HC”) is at will. Position: SVP, General Counsel and Corporate Secretary Division/Department: Gen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

Offer Letter, dated March 27, 2023, between the Registrant and Anne Marie Bickmore.

Exhibit 10.1 March 27, 2023 Dear Anne Marie, We are pleased to extend to you an offer for a new position with Health Catalyst. This offer is subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for employment; and employment with Health Catalyst (“HC”) is at will. Position: Chief Operating Officer and Chief Product Officer Division/Dep

Health Catalyst Reports First Quarter 2023 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2023 Results SALT LAKE CITY, UT, May 9, 2023 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2023. “In the first quarter of 2023, I am pleased to share that we achieved strong per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 HEALTH CATALYST, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 HEALTH CATALYST, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 HEALTH CATALYST, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

As filed with the U.S. Securities and Exchange Commission on February 28, 2023

As filed with the U.S. Securities and Exchange Commission on February 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Iden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Health Catalyst Australia PTY LTD (Australia) Health Catalyst UK Ltd (England and Wales) Health Catalyst India Private Limited (India) Health Catalyst Singapore Pte. Ltd. (Singapore) Health Catalyst Middle East FZ-LLC (incorporated within a Free Zone in the UAE) Able Health, LLC (Delaware, United States) ARMUS I LLC (Delaware, United State

Innovative Healthcare Executive and Carle Health COO Matthew Kolb Joins Health Catalyst Board of Directors; Carle Health Becomes Health Catalyst Shareholder

Exhibit 99.1 Innovative Healthcare Executive and Carle Health COO Matthew Kolb Joins Health Catalyst Board of Directors; Carle Health Becomes Health Catalyst Shareholder Salt Lake City, UT – February 28, 2023 – Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Matthew Kolb, Exe

on-Employee Director Compensation Policy.

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

Health Catalyst Reports Fourth Quarter and Year End 2022 Results

Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2022 Results SOUTH JORDAN, UT, February 28, 2023 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2022. “In the fourth quarter of 2022, I am pleased to sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 HEALTH CATALYST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Filing Fee Table

Calculation of Filing Fee Tables Form S-8 (Form Type) Health Catalyst, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed maximum offering price per unit Maximum aggregate offering price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value p

Offer Letter, dated August 7, 2020, between the Registrant and Kevin Freeman.

Exhibit 10.6 August 07, 2020 Dear Kevin, We are pleased to extend you this offer of employment with Health Catalyst (“HC”). This offer is subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for employment; and employment with Health Catalyst (“HC”) is at will. Position: SVP, Sales Vitalware Base salary: $250,000 annually Start date: T

ase Agreement, dated December 30, 2022, between the Registrant and J. Patrick Nelli

Exhibit 10.16 Separation and Release Agreement This Separation and Release Agreement (the “Agreement”) is made and entered into as of the last date on the signature page (the “Effective Date”) and confirms the following understandings and agreements among Health Catalyst, Inc. (“Health Catalyst” or the “Company”) and James Patrick Nelli (hereinafter referred to as “you” or “your”). WHEREAS, you wer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HEALTH CATALYST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

HCAT / Health Catalyst Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Health Catalyst, Inc. (Title of Class of Secur

HCAT / Health Catalyst Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Health Catalyst Inc (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

HCAT / Health Catalyst Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

HCAT / Health Catalyst Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01052-healthcatalystinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Health Catalyst Inc. Title of Class of Securities: Common Stock CUSIP Number: 42225T107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desig

HCAT / Health Catalyst Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

HCAT / Health Catalyst Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G/A 1 HCATSC13GA2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) HEALTH CATALYST, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 42225T107 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appro

Overview Presentation January 2023 © Health Catalyst. Confidential and proprietary. 2 Disclaimer This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical

EX-99.1 2 healthcatalystjpmovervi.htm EX-99.1 Overview Presentation January 2023 © Health Catalyst. Confidential and proprietary. 2 Disclaimer This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations and financi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commissi

Health Catalyst Announces New, External Leadership Assignment for Paul Horstmeier

Exhibit 99.1 Health Catalyst Announces New, External Leadership Assignment for Paul Horstmeier Salt Lake City, UT ? January 6, 2023 ? Health Catalyst, Inc. (?Health Catalyst,? Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that the leadership of the Church of Jesus Christ of Latter-Day Saints has called Paul Horstmeier,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Reports Third Quarter 2022 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2022 Results SALT LAKE CITY, UT, November 8, 2022 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2022. ?In the third quarter of 2022, I am pleased to share that we achieved s

HCAT / Health Catalyst Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Health Catalyst, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Announces New Leadership Assignments in Support of Strategic Focus Areas

Exhibit 99.1 Health Catalyst Announces New Leadership Assignments in Support of Strategic Focus Areas Announces Appointments of Kevin Freeman as Chief Growth Officer, Tarah Neujahr Bryan as Chief Marketing Officer, and Dave Ross as Chief Technology Officer. Salt Lake City, UT ? September 7, 2022 ? Health Catalyst, Inc. (?Health Catalyst,? Nasdaq: HCAT), a leading provider of data and analytics tec

HCAT / Health Catalyst Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 HEALTH CATALYST, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 42225T107 (CUSIP Number) AUGUST 22, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which

HCAT / Health Catalyst Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Health Catalyst Inc. Title of Class of Securities: Common Stock CUSIP Number: 42225T107 Date of Event Which Requires Filing of this Statement: July 29, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Health Catalyst Announces $40 Million Share Repurchase Program

Exhibit 99.1 Health Catalyst Announces $40 Million Share Repurchase Program SALT LAKE CITY, UT, August 4, 2022 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that its board of directors approved a share repurchase program with authorization to purchase up to $40 million of its

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Health Catalyst Reports Second Quarter 2022 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2022 Results SALT LAKE CITY, UT, August 4, 2022 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2022. ?I am pleased to share that Q2 2022 marked another quarter of strong financia

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Health Catalyst Reports First Quarter 2022 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2022 Results SALT LAKE CITY, UT, May 10, 2022 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2022. ?In the first quarter of 2022, I am pleased to share that we began the year by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 a2022proxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

As filed with the U.S. Securities and Exchange Commission on March 1, 2022

As filed with the U.S. Securities and Exchange Commission on March 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Identifi

Filing Fee Table

Calculation of Filing Fee Tables Form S-8 (Form Type) Health Catalyst, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed maximum offering price per unit Maximum aggregate offering price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value p

Offer Letter, dated January 13, 2012, between the Registrant and Bryan Hinton.

Exhibit 10.6 Friday, January 13, 2012 Dear Bryan Hinton, This letter represents an offer of full-time employment, subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for employment and employment with HQC is at will. Position: Sr. Software Architect Base salary: $135,000.00 Annualized Start date: On or before January 30, 2012 Division

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Medicity LLC (Delaware, United States) Health Catalyst UK Ltd (England and Wales) Health Catalyst Singapore Pte. Ltd. (Singapore) Health Catalyst Middle East FZ-LLC (incorporated within a Free Zone in the UAE) Able Health, LLC (Delaware, United States) Healthfinch, LLC (Delaware, United States) Vitalware, LLC (Delaware, United States) Twis

Health Catalyst Reports Fourth Quarter and Year End 2021 Results

Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2021 Results SOUTH JORDAN, UT, March 1, 2022 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2021. ?In the fourth quarter of 2021, I am pleased to share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

HCAT / Health Catalyst Inc / ALLIANCEBERNSTEIN L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Health Catalyst Inc (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

HCAT / Health Catalyst Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

HCAT / Health Catalyst Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Health Catalyst Inc. Title of Class of Securities: Common Stock CUSIP Number: 42225T107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

HCAT / Health Catalyst Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Health Catalyst Reports Third Quarter 2021 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2021 Results SALT LAKE CITY, UT, November 9, 2021 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2021. ?In the third quarter of 2021, I am pleased to share that we achieved s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission F

Underwriting Agreement, dated as of August 10, 2021, among Health Catalyst, Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein.

Exhibit 1.1 Health Catalyst, Inc. Common Stock, par value $0.001 per share Underwriting Agreement August 10, 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC Evercore Group L.L.C. As representatives (the ?Representatives? or ?you?) of the several Underwriters named in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200

4,245,283 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-258625 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2021) 4,245,283 Shares Common Stock We are offering 4,245,283 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?HCAT.? The last reported sale price of our common stock on August 10, 2021 was $54.65 per share. Investing

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

SUBJECT TO COMPLETION, DATED AUGUST 9, 2021.

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-258625 The information in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying base prospectus a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Health Catalyst Reports Second Quarter 2021 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2021 Results SALT LAKE CITY, UT, August 5, 2021 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2021. ?In the second quarter of 2021, I am pleased to share that we achieved strong

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Amendment to the Amended and Restated Bylaws

AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF HEALTH CATALYST, INC. (the ?Corporation?) Section 8 of Article VI of the Amended and Restated Bylaws of the Corporation (the ?Bylaws?), is hereby amended and restated in its entirety as follows: ?SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States District Court. Unless the Corporation consents in writing to the selection of an

© 2021 Health Catalyst Twistle Overview  Patient engagement software that automates personalized communication between care teams and patients, leveraging rich clinical content o Primarily serves healthcare providers & risk bearing entities as well

? 2021 Health Catalyst Twistle Overview ? Patient engagement software that automates personalized communication between care teams and patients, leveraging rich clinical content o Primarily serves healthcare providers & risk bearing entities as well as a few life sciences companies ? Multi-channel communication enabled by deep integrations with EMRs, IoT smart devices, and third- party services an

Health Catalyst Announces Agreement to Acquire Twistle Twistle, a Patient Engagement SaaS Technology Solution, to Enhance Health Catalyst’s Population Health Offering and Enable More Comprehensive Support for Organizations Transitioning to Population

Exhibit 99.1 Health Catalyst Announces Agreement to Acquire Twistle Twistle, a Patient Engagement SaaS Technology Solution, to Enhance Health Catalyst?s Population Health Offering and Enable More Comprehensive Support for Organizations Transitioning to Population Health Care Models Salt Lake City, Utah ? June 24, 2021 ? Health Catalyst, Inc. (?Health Catalyst,? Nasdaq: HCAT), a leading provider of

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Quarterly Report - 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

Health Catalyst Reports First Quarter 2021 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2021 Results SALT LAKE CITY, UT, May 6, 2021 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2021. ?In the first quarter of 2021, I am pleased to share that we achieved strong per

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

- DEF 14A

DEF 14A 1 a2021proxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- S-8

As filed with the U.S. Securities and Exchange Commission on February 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Iden

Health Catalyst Reports Fourth Quarter and Year End 2020 Results

Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2020 Results SOUTH JORDAN, UT, February 25, 2021 ? Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2020. ?In the fourth quarter of 2020, I am pleased to sh

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Offer Letter, dated April 4, 2013, between the Registrant and Jason Alger.

Exhibit 10.15 April 4, 2013 Jason Alger Dear Jason, We are pleased to extend to you this offer of full-time employment with Health Catalyst. We are confident that your skills, experience and hard work will contribute meaningfully to the success of the company. This offer is subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement for emplo

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Offer Letter, dated March 27, 2014, between the Registrant and Bryan Hunt.

Exhibit 10.10 Thursday, March 27, 2014 Dear Bryan Hunt, We are pleased to extend to you this offer of full-time employment with Health Catalyst. We are confident that your skills, experience and hard work will contribute mean ingfu ll y to the success of the company. This offer is subject to the terms and conditions set forth in this offer. This letter does not represent a contract or agreement fo

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Medicity LLC (Delaware, United States) Health Catalyst UK Ltd (England and Wales) Health Catalyst Singapore Pte. Ltd. (Singapore) Able Health, LLC (Delaware, United States) Healthfinch, LLC (Delaware, United States) Vitalware, LLC (Delaware, United States)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exc

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Numb

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Health Catalyst Inc. Title of Class of Securities: Common Stock CUSIP Number: 42225T107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Ru

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

Health Catalyst Reports Third Quarter 2020 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2020 Results SALT LAKE CITY, UT, November 10, 2020 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2020. “In the third quarter of 2020, I am pleased to share that we achieved strong performance

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Health Catalyst Promotes Patrick Nelli to the Role of President Announces Promotion of Bryan Hunt as CFO and Additional Leadership Responsibilities to Support Continued Growth and Expansion

Exhibit 99.2 Health Catalyst Promotes Patrick Nelli to the Role of President Announces Promotion of Bryan Hunt as CFO and Additional Leadership Responsibilities to Support Continued Growth and Expansion SALT LAKE CITY, UT, November 10, 2020 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

Health Catalyst Completes Hosting of the Largest Ever Healthcare Analytics Summit and Announces the Close of the Vitalware Acquisition Company Moves Forward with Co-Founder’s Return and Leadership Transitions

Exhibit 99.1 Health Catalyst Completes Hosting of the Largest Ever Healthcare Analytics Summit and Announces the Close of the Vitalware Acquisition Company Moves Forward with Co-Founder’s Return and Leadership Transitions SALT LAKE CITY, UT, September 8, 2020 — The board of directors (the “Board”) of Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Quarterly Report - 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Health Catalyst Reports Second Quarter 2020 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2020 Results SALT LAKE CITY, UT, August 11, 2020 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2020. “First, let me express our ongoing gratitude to all the heroic national health systems and thei

Vitalware Overview & Strategic Rationale for Acquisition • Offers a revenue workflow optimization and analytics SaaS technology solution • Flagship offering is a best-in-KLAS Chargemaster workflow solution • Also offers newer product suites in: - Rev

vitalwareirxslides Vitalware Overview & Strategic Rationale for Acquisition • Offers a revenue workflow optimization and analytics SaaS technology solution • Flagship offering is a best-in-KLAS Chargemaster workflow solution • Also offers newer product suites in: - Revenue Integrity to capture lost revenue Overview - Price Transparency to support compliance with expanding pricing transparency regu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission F

Health Catalyst Announces Agreement to Acquire Vitalware, a Revenue Workflow Optimization and Analytics SaaS Technology Solution

Exhibit 99.1 Health Catalyst Announces Agreement to Acquire Vitalware, a Revenue Workflow Optimization and Analytics SaaS Technology Solution SALT LAKE CITY, UT, August 11, 2020 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to ac

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Lease agreement, dated as of March 25, 2020, between Riverpark Six, LLC and Health Catalyst, Inc.

Exhibit 10.1 LEASE RiverPark Corporate Center—Building Six between RIVERPARK SIX, LLC, a Utah limited liability company, as Landlord, and HEALTH CATALYST, INC., a Delaware corporation, as Tenant Dated March 25, 2020 TABLE OF CONTENTS Paragraph Page 1. Definitions 1 2. Agreement of Lease; Work of Improvement; Certain References 12 3. Term; Commencement Date; Tenant Rights 14 4. Basic Monthy Rent 21

Quarterly Report - 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

Health Catalyst Reports First Quarter 2020 Results

Exhibit 99.1 Health Catalyst Reports First Quarter 2020 Results SALT LAKE CITY, UT, May 12, 2020 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2020. “Let me first take this opportunity to share that our thoughts and prayers are with all those impa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission File

Mark Templeton Appointed to Health Catalyst Board of Directors

Exhibit 99.1 Mark Templeton Appointed to Health Catalyst Board of Directors SALT LAKE CITY, UT, May 12, 2020 — The board of directors (the “Board”) of Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, named Mark Templeton to its Board and its nominating and corporate governance committee, effective

- DEF 14A

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta

- DEFA14A

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta

Form of Global Note, representing Health Catalyst, Inc.'s 2.50% Convertible Senior Notes due 2025 (included as Exhibit A to the Indenture filed as Exhibit 4.1).

Exhibit 4.1 HEALTH CATALYST, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 14, 2020 2.50% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 14 Section 2.01 Designation and Amount 14 Section 2.0

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Form of Confirmation for Capped Call Transactions.

Exhibit 10.1 April [], 2020 From: [Dealer] [] [] [] To: Health Catalyst, Inc. 3165 Millrock Drive #400 Salt Lake City, UT 84121 Attention: Jason Alger, Senior Vice President Email: [email protected] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into

Health Catalyst, Inc. Prices Upsized Offering of $200 million 2.50% Convertible Senior Notes Due 2025

Exhibit 99.2 Health Catalyst, Inc. Prices Upsized Offering of $200 million 2.50% Convertible Senior Notes Due 2025 SALT LAKE CITY, UT, - April 8, 2020 – Health Catalyst, Inc. (Nasdaq: HCAT) (the “Company” or “Health Catalyst”) announced today the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) in a private offering (the “offering”) to q

Health Catalyst, Inc. Announces Proposed Offering of $175 Million Convertible Senior Notes

Exhibit 99.1 Health Catalyst, Inc. Announces Proposed Offering of $175 Million Convertible Senior Notes SALT LAKE CITY, UT, - April 8, 2020 – Health Catalyst, Inc. (Nasdaq: HCAT) (the “Company” or “Health Catalyst”) announced today that it intends to offer, subject to market conditions and other factors, $175.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) i

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fil

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission Fi

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Health Catalyst, Inc. Medicity LLC (Delaware, United States) Health Catalyst UK Ltd (England and Wales) Health Catalyst Singapore Pte. Ltd. (Singapore) Able Health LLC (Delaware, United States)

Description of securities registered under Section 12 of the Exchange Act.

Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2019, Health Catalyst, Inc. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock The following descri

As filed with the U.S. Securities and Exchange Commission on February 28, 2020

As filed with the U.S. Securities and Exchange Commission on February 28, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State or other jurisdiction of incorporation) (IRS Employer Iden

HCAT / Health Catalyst, Inc 10-K - Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38

Health Catalyst Reports Fourth Quarter and Year End 2019 Results

EX-99.1 2 a2019yeexhibit991-pres.htm EX-99.1 Exhibit 99.1 Health Catalyst Reports Fourth Quarter and Year End 2019 Results SALT LAKE CITY, UT, February 27, 2020 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2019. “We concluded an excep

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

HCAT / Health Catalyst, Inc / SC US GF V Holdings, Ltd. - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* HEALTH CATALYST, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number)

HCAT / Health Catalyst, Inc / Norwest Venture Partners XI, LP - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Health Catalyst, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42225T107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

HCAT / Health Catalyst, Inc 10-Q - Quarterly Report - 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEA

Health Catalyst Reports Third Quarter 2019 Results

Exhibit 99.1 Health Catalyst Reports Third Quarter 2019 Results SALT LAKE CITY, UT, November 12, 2019 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the third quarter ended September 30, 2019. “In the third quarter of 2019, I am pleased that we achieved strong performance acr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Experienced Technology Executives Julie Larson-Green and S. Dawn Smith appointed to Health Catalyst Board of Directors

Exhibit 99.1 Experienced Technology Executives Julie Larson-Green and S. Dawn Smith appointed to Health Catalyst Board of Directors SALT LAKE CITY, UT, November 12, 2019 — The board of directors (the “Board”) of Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, appointed Julie Larson-Green and S. D

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission

Non-Employee Director Compensation Policy.

Exhibit 10.1 HEALTH CATALYST, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Health Catalyst, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Com

HCAT / Health Catalyst, Inc 10-Q - Quarterly Report - 10-Q

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38993 HEALTH C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2019 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 001-38993 45-3337483 (State or other jurisdiction of incorporation) (Commission F

Health Catalyst Reports Second Quarter 2019 Results

Exhibit 99.1 Health Catalyst Reports Second Quarter 2019 Results SALT LAKE CITY, UT, August 22, 2019 — Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the second quarter ended June 30, 2019. "Our second quarter results showcase consistent performance across the business. Strong

7,000,000 Shares Common Stock

Filed pursuant to Rule 424(b)(4) Registration No. 333-232400 7,000,000 Shares Common Stock This is the initial public offering of shares of common stock of Health Catalyst, Inc. We are offering 7,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per share is $26.00. We have been approved to list our c

HCAT / Health Catalyst, Inc S-8 - - S-8

As filed with the U.S. Securities and Exchange Commission on July 24, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Health Catalyst, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 45-3337483 (I.R.S

HCAT / Health Catalyst, Inc CORRESP - -

July 23, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

HCAT / Health Catalyst, Inc CORRESP - -

Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 July 23, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jan Woo Mitchell Austin Stephen Krikorian Diane Fritz Re: Health Catalyst, Inc. Withdrawal of Acceleration Request for Reg

As filed with the Securities and Exchange Commission on July 23, 2019.

As filed with the Securities and Exchange Commission on July 23, 2019. Registration Statement No. 333-232400 . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) Delaware 7389 45-3337483 (State or other jurisdiction of

HCAT / Health Catalyst, Inc CORRESP - -

Health Catalyst, Inc. 3165 Millrock Drive #400 Salt Lake City, UT 84121 VIA EDGAR July 23, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jan Woo Mitchell Austin Stephen Krikorian Diane Fritz Re: Health Catalyst, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-232400 Ladies and Gentlemen: Purs

HCAT / Health Catalyst, Inc CORRESP - -

Health Catalyst, Inc. 3165 Millrock Drive #400 Salt Lake City, UT 84121 VIA EDGAR July 22, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jan Woo Mitchell Austin Stephen Krikorian Diane Fritz Re: Health Catalyst, Inc. Withdrawal of Acceleration Request for Registration Statement on Form S-1 File No. 333-232400 Ladies and G

HCAT / Health Catalyst, Inc CORRESP - -

July 19, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

HCAT / Health Catalyst, Inc CORRESP - -

Health Catalyst, Inc. 3165 Millrock Drive #400 Salt Lake City, UT 84121 VIA EDGAR July 19, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jan Woo Mitchell Austin Stephen Krikorian Diane Fritz Re: Health Catalyst, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-232400 Ladies and Gentlemen: Purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Health Catalyst, Inc. (Exact name of registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Health Catalyst, Inc. (Exact name of registrant as specified in its charter) Delaware 45-3337483 (State of incorporation or organization) (I.R.S. Employer Identification No.) 3165 Millrock Drive #4

Amended and Restated Bylaws.

Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF HEALTH CATALYST, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may sub

2019 Stock Option and Incentive Plan, and forms of agreements thereunder.

Exhibit 10.12 HEALTH CATALYST, INC. 2019 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Health Catalyst, Inc. 2019 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Health Catalyst, Inc. (the ?Company?) and its Affiliates

2019 Employee Stock Purchase Plan.

Exhibit 10.14 HEALTH CATALYST, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Health Catalyst, Inc. 2019 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Health Catalyst, Inc. (the ?Company?) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stoc

Amendment No. 1 to Financing Documents, dated July 10, 2019, by and among the Registrant and certain of its stockholders.

Exhibit 4.5 AMENDMENT NO. 1 TO FINANCING DOCUMENTS This Amendment No.1 to the Financing Documents (this ?Amendment?) is made as of July 10, 2019, by and among Health Catalyst, Inc., a Delaware corporation (the ?Company?) and the parties listed on the signature pages hereto (the ?Stockholders?). WHEREAS, pursuant to Section 3F of that certain Health Catalyst, Inc. Fifth Amended and Restated Investo

Form of common stock certificate.

Exhibit 4.1 HC INCORPORATED UNDER THE CUSIP 42225T 10 7 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: REGISTERED: COUNTERSIGNED AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Health Catalyst, Inc. transfe

Form of Underwriting Agreement.

Exhibit 1.1 Health Catalyst, Inc. Common Stock, par value $0.001 per share Underwriting Agreement [?], 2019 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC As representatives (the ?Representatives? or ?you?) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New Y